bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. filed an 8-K on July 7, 2026, announcing continued acceleration in commercial sales for CyPath® Lung, its noninvasive lung cancer diagnostic. The company reported more than 200% year‑over‑year growth in commercial sales and attached a press release dated July 7, 2026 (Exhibit 99.1).

Key Details

• Filing date: July 7, 2026 (Form 8-K, Item 8.01 Other Events).
• Product: CyPath® Lung — a noninvasive diagnostic for lung cancer.
• Reported growth: more than 200% year‑over‑year increase in commercial sales.
• Press release attached as Exhibit 99.1 and incorporated by reference.

Why It Matters
A reported >200% YoY increase in commercial sales indicates accelerating market adoption of CyPath® Lung, which could be an important driver of future revenue growth for bioAffinity. Retail investors should note the claim and watch upcoming quarterly (10-Q) and annual (10-K) filings or subsequent press releases for concrete revenue figures, margins, and recurring sales trends to assess how sales growth translates into company financial results.